LGND

#1273
Ligand Pharmaceuticals Inc.
198.3100
+1.83%
版块:
基础:
利润货币:
日范围
198.3100
198.3100
年范围
175.8900
212.4900
日变化
+1.83%
每月变动
+1.39%
6个月变化
+5.98%
年变化
+5.98%
前一天收盘价
194.7425
Open
198.3100
Bid
Ask
Low
198.3100
High
198.3100
交易量
58
Open full chart

Financials

Overview 声明 Statistics Dividends
Quarterly Annual
  • Market Capitalization 3.8825 B
  • Employee 68
  • Founded N/A
  • CEO N/A
  • Website www.ligand.com
  • Headquarter Delaware, United States
  • FIGI BBG000BKF014
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
88.13
Price to sales ratio
13.96
Dividends per share
—
Dividend yield %
—

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol. The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments. Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020.

新闻